![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 06, 2020 3:32:46 PM
9+ YEARS with not a single verifiable accomplishment
Nuvilex Enters Discussions to Acquire Next Generation Technology to Treat Multiple Types of Cancer
June 14, 2011 09:47 AM Eastern Daylight Time
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) announced today it has entered into discussions to acquire the next generation live cell encapsulation technology that serves as the platform for multiple cancer therapies.
“Good for You, Good for the Environment.”
Tweet this
While the recently acquired pancreatic cancer therapy is a single-use derivative of the live cell encapsulation technology, the acquisition of the underlying platform would enable Nuvilex to pursue a substantial variety of other cancer applications.
Cell encapsulation allows placement of any cell type into the body after enclosing the cells inside tiny beads. Depending on the cell type placed into the beads, or encapsulated, these cells enable continuous and/or controlled production and release of therapeutic molecules. This includes activated drugs, as is the case with the pancreatic cancer treatment technology already owned by Nuvilex.
The beads are made of a naturally occurring, nontoxic, biocompatible material that protects the encapsulated cells from attack by the body's defence mechanisms. At the same time, the beads provide a microenvironment that enables encapsulated cells to survive for long periods of time.
Dr. Robert F. Ryan, Corporate Executive of Nuvilex commented, “We consider the benefits of using the cell encapsulation technology for pancreatic cancer treatment to be extensive. Through the use of this technology, we believe we will be able to extend the lifespan of patients with advanced pancreatic cancer as well as giving them a better quality of life while they endure their disease. We also feel cell encapsulation may prove useful in the treatment of cancers other than pancreatic and are interested in this potential extension of what we have already acquired from SG Austria.”
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM